Skip to main content
. Author manuscript; available in PMC: 2016 Jun 24.
Published in final edited form as: Future Oncol. 2015;11(5):719–733. doi: 10.2217/fon.14.272

Table 3.

Hematologic laboratory test abnormalities in the COMFORT trials during randomized treatment

COMFORT-I [33] COMFORT-II [34]

Event, Percentage of patients Ruxolitinib (n = 155) Placebo (n = 151) Ruxolitinib (n = 146) BAT (n = 73)
Anemia
 All grades 96.1 86.8 96 94
 Grade ≥3 45.2 19.2 42 31
Thrombocytopenia
 All grades 69.7 30.5 68 29
 Grade ≥3 12.9 1.3 8 7
Neutropenia
 All grades 18.7 4.0 NR NR
 Grade ≥3 7.1 2.0 NR NR

BAT: Best available therapy; NR: Not reported.